CHICAGO - Abbott Laboratories, Hoescht Marion Roussel, Pharmacia & Upjohn and Rhone-Poulenc Rorer followed the precedent set by 11 other pharmaceutical manufacturers last month when they tentatively agreed to settle a class-action lawsuit brought against them by Walgreen Co. and other retail pharmacies.
CHICAGO - Abbott Laboratories, Hoescht Marion Roussel, Pharmacia & Upjohn and Rhone-Poulenc Rorer followed the precedent set by 11 other pharmaceutical manufacturers last month when they tentatively agreed to settle a class-action lawsuit brought against them by Walgreen Co. and other retail pharmacies.
The lawsuit, which was filed in 1993, alleged that pharmaceutical companies were involved in conspiratorial discounting and pricing practices that violated federal and state antitrust laws. They did so, the plaintiffs claim, by conspiring to impose a dual pricing system on its customers, granting discounts to managed care companies and not to retail pharmacies. The retail pharmacies argued that this unfairly passed higher costs on to them and their uninsured and underinsured customers.
Pharmaceutical manufacturers said they were justified in charging HMOs and hospitals less because the organizations are able to control the drugs their patients use, and therefore offer manufacturers greater assurance of sales.
In the settlement, Abbott Laboratories agreed to pay the plaintiffs $57 million, Hoescht Marion Roussel agreed to pay $149.5 million, Pharmacia & Upjohn agreed to pay $102.5 million and Rhone-Poulenc Rorer agreed to pay $33.9 million. Combined with previous settlements, the monies bring the total settlement figure to more than $700 million.
Two of the settling companies released statements reiterating that they felt they acted ethically and lawfully, but had agreed to settle in order to avoid lengthy, uncertain legal battles that could have hurt their shareholders and stakeholders.
"There was no conspiracy, and we believe we would have prevailed at trial," said Gerald P. Belle, president of Hoescht Marion Roussel North America. "The simple fact, however, is the class-action system allows plaintiffs' lawyers to put together such huge damage claims that even a small possibility that a jury could come to the wrong conclusion poses substantial risk to the company."
In a prepared statement, Pharmacia & Upjohn said it settled in order "to limit its financial exposure and to avoid a lengthy, costly and uncertain jury trial." The company added that the decision was made in the best interests of its business, and that it settled in order to focus on its "continuing turnaround and growth efforts."
Only four of the original 19 pharmaceutical manufacturers remain plaintiffs in the case, including Johnson & Johnson and Searle. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.